A leader in the discovery of oral direct-acting antiviral therapies.

Atea’s most advanced antiviral drug candidate, AT-527, is being evaluated in MORNINGSKY, a global multi-center Phase 3 clinical trial for the treatment of patients with mild or moderate COVID-19 in an outpatient setting. As an orally-administered direct-acting antiviral, AT-527 is designed to arrest the progression of COVID-19 by inhibiting replication of the SARS CoV-2 virus.

Learn More


Innovative discovery and efficient development of potentially transformative therapies for patients with life-threatening viral diseases.

Atea is a clinical stage biopharmaceutical company working to address unmet medical needs with innovative oral antiviral therapies.


The power of our purine nucleotide prodrug platform.

Leveraging our platform, we have discovered and are rapidly advancing novel oral direct-acting antiviral drug candidates. Utilizing unique chemical modifications, these product candidates are designed to have the potential for enhanced antiviral activity and selectivity.

A network of hubs and spokes is suspended, representing the idea of a modular platform.


AT-527 addresses the key challenges of the COVID-19 pandemic and beyond.

For the treatment of COVID-19, we need transformational solutions, and we believe that oral, safe, direct-acting antivirals can play an essential role worldwide. The value and global health impact of a direct-acting antiviral is to rapidly inhibit viral replication in the early phase of infection, which has the effect of reducing disease progression and curtailing the spread of infection.

While vaccines will play an important role in mitigating the COVID-19 pandemic, we will need treatment options to stay ahead of the virus. To treat patients who are waiting to or do not want to be immunized and for patients for whom the vaccine does not create protective immunity, direct-acting antivirals are and will remain an essential complement to vaccines.

AT-527 is an oral, direct-acting antiviral drug candidate.

AT-527 is being evaluated for easy and early administration to reduce burden and duration of disease. AT-527 has the potential to be used for pre- and post-exposure prophylaxis, to reduce transmission and to impact long-term COVID sequelae.

Similar to Tamiflu®

Complementary medical intervention to vaccination similar to the influenza paradigm (Tamiflu®)

Significant advantages vs antibodies

Significant advantages vs antibodies:

  • convenient for patients and healthcare workers
  • global reach
  • manufacture
  • scale-up
  • cost
Effective vs. mutations

Highly-conserved target has potential to enable antiviral activity in the presence of multiple variants

anticipated to be effective again st future coronaviruses

Antiviral activity against potential future coronaviruses beyond SARS-CoV-2 anticipated


Follow our progress.

See updates on AT-527, other Atea product candidates and company news.

Atea Pharmaceuticals Highlights Strategic Priorities for 2022

COVID-19 : Planning global Phase 2 outpatient trial for bemnifosbuvir (AT-527) designed to support anticipated combination trials HCV : Obtained from Merck an exclusive worldwide license to ruzasvir (RZR), a Phase 2-ready, oral, potent NS5A inhibitor for development in combination with

Atea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present at the 40 th Annual J.P.

Atea Pharmaceuticals Added to the Nasdaq Biotechnology Index

BOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the company has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.